Shares of Halozyme Therapeutics HALO rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 247.37% over the past year to $0.66, which beat the estimate of $0.40.
Revenue of $136,455,000 up by 147.11% from the same period last year, which beat the estimate of $103,160,000.
Outlook
The upcoming fiscal year's EPS expected to be between $1.85 and $2.00.
The upcoming fiscal year's revenue expected to be between $425,000,000 and $445,000,000.
Details Of The Call
Date: Aug 09, 2021
Time: 04:30 PM
Recent Stock Performance
Company's 52-week high was at $56.40
52-week low: $25.17
Price action over last quarter: Up 0.75%
Company Profile
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
